FDA (CDER)
GUIDANCE FINAL
Q8, Q9, and Q10 Questions and Answers (R5)
Published: 5/29/2026Detected: 5/29/2026
Summary preview
Provides final Q&A clarifications on ICH Q8/Q9/Q10 implementation topics, which may influence how sponsors define pharmaceutical development, manage quality risk, and implement an effective pharmaceutical quality…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#ICH Q8
#ICH Q9
#ICH Q10
#pharmaceutical quality system
#quality risk management
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
- Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry9/8/2026
- Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
- Evaluation of Therapeutic Equivalence8/21/2026
- Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026